BACKGROUND: Neovascular glaucoma (NVG) is a potentially blinding disease associated with ocular ischaemia. Use of an anti-vascular endothelial growth factor agent has been reported as a treatment option for NVG. The purpose of this study was to investigate initial results regarding the treatment of NVG with intravitreal aflibercept. DESIGN: This study employed a prospective, interventional case series study design. PARTICIPANTS: Patients with newly diagnosed stage 1 or 2 neovascular glaucoma were eligible to participate in this study. METHODS: Four patients with newly diagnosed stage 1 or 2 NVG were treated with intravitreal aflibercept at the time of diagnosis, with planned repeat injection at 4 weeks, 8 weeks and then every 8 weeks thereafter up until 52 weeks after study initiation. MAIN OUTCOME MEASURES: Primary outcomes were regression of neovascularization of the iris and angle (NVI, NVA). Secondary outcome measurements included visual acuity and intraocular pressure (IOP). RESULTS: Intravitreal aflibercept resulted in rapid regression of NVI and NVA. IOP was stable or reduced in all patients at the 52-week study visit. CONCLUSIONS: These results suggest that intravitreal aflibercept may be an effective treatment for stage 1 and 2 NVG, resulting in rapid and sustained regression of NVI and NVA as well as control of IOP. Further research is needed to determine the full duration of effect and the optimal dose and timing of administration.
BACKGROUND:Neovascular glaucoma (NVG) is a potentially blinding disease associated with ocular ischaemia. Use of an anti-vascular endothelial growth factor agent has been reported as a treatment option for NVG. The purpose of this study was to investigate initial results regarding the treatment of NVG with intravitreal aflibercept. DESIGN: This study employed a prospective, interventional case series study design. PARTICIPANTS: Patients with newly diagnosed stage 1 or 2 neovascular glaucoma were eligible to participate in this study. METHODS: Four patients with newly diagnosed stage 1 or 2 NVG were treated with intravitreal aflibercept at the time of diagnosis, with planned repeat injection at 4 weeks, 8 weeks and then every 8 weeks thereafter up until 52 weeks after study initiation. MAIN OUTCOME MEASURES: Primary outcomes were regression of neovascularization of the iris and angle (NVI, NVA). Secondary outcome measurements included visual acuity and intraocular pressure (IOP). RESULTS: Intravitreal aflibercept resulted in rapid regression of NVI and NVA. IOP was stable or reduced in all patients at the 52-week study visit. CONCLUSIONS: These results suggest that intravitreal aflibercept may be an effective treatment for stage 1 and 2 NVG, resulting in rapid and sustained regression of NVI and NVA as well as control of IOP. Further research is needed to determine the full duration of effect and the optimal dose and timing of administration.
Authors: Gustavo B Rodrigues; Ricardo Y Abe; Camila Zangalli; Savio L Sodre; Flavia A Donini; Danilo C Costa; Andre Leite; Joao P Felix; Marcelo Torigoe; Alberto Diniz-Filho; Homero Gusmão de Almeida Journal: Int J Retina Vitreous Date: 2016-11-14
Authors: Gabriel Lazcano-Gomez; Jeffrey R Soohoo; Anne Lynch; Levi N Bonell; Karina Martinez; Mauricio Turati; Roberto Gonzalez-Salinas; Jesus Jimenez-Roman; Malik Y Kahook Journal: J Curr Glaucoma Pract Date: 2017-08-05